Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene
- PMID: 32512165
- DOI: 10.1016/j.bone.2020.115469
Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene
Erratum in
-
Corrigendum to "Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene" [Bone 138 (2020) 115469].Bone. 2024 Feb;179:116962. doi: 10.1016/j.bone.2023.116962. Epub 2023 Nov 18. Bone. 2024. PMID: 37984130 No abstract available.
Abstract
The human ACVR1 gene encodes a transmembrane protein consisting of 509 amino acids called activin A receptor, type I (ACVR1) or activin receptor-like kinase 2 (ALK2) and has nine coding exons. The ALK2 protein functions as a signaling receptor for ligands of the transforming growth factor-β family. In the human ACVR1 gene, approximately 20 types of heterozygotic mutations in the coding exons have been associated with congenital disorders and somatic cancer, such as fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma, diffuse idiopathic skeletal hyperostosis and some congenital heart disorders. In the present study, we designed primers for direct sequencing of the nine coding exons in the human ACVR1 gene. The reliability of the primers was examined by PCR and DNA sequencing using genomic DNA prepared from peripheral blood or swab samples of three patients with FOP who had different mutations in the ACVR1 gene. A single nucleotide heterozygotic mutation was identified in each genomic sample without additional mutations in other regions. Therefore, the primers designed for the nine coding exons of the ACVR1 gene could be useful for the genetic diagnosis of patients who may have disorders associated with mutations in the ACVR1 gene.
Keywords: ACVR1; Fibrodysplasia ossificans progressiva; Genetic diagnosis.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest T.K. received research grants from Daiichi-Sankyo, Co. Ltd. The other authors declare no conflicts of interest in association with the present study.
Similar articles
-
Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.Methods Mol Biol. 2018;1828:497-502. doi: 10.1007/978-1-4939-8651-4_32. Methods Mol Biol. 2018. PMID: 30171563
-
[A Chinese girl with fibrodysplasia ossificans progressiva caused by a de novo mutation R206H in ACVR1 gene].Zhonghua Er Ke Za Zhi. 2008 Mar;46(3):215-9. Zhonghua Er Ke Za Zhi. 2008. PMID: 19099712 Chinese.
-
ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.Am J Med Genet A. 2014 Jan;164A(1):220-4. doi: 10.1002/ajmg.a.36219. Epub 2013 Nov 20. Am J Med Genet A. 2014. PMID: 24259422 Review.
-
The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.Eur J Med Genet. 2017 Jul;60(7):399-402. doi: 10.1016/j.ejmg.2017.04.013. Epub 2017 May 1. Eur J Med Genet. 2017. PMID: 28473268
-
ACVR1 mutations in DIPG: lessons learned from FOP.Cancer Res. 2014 Sep 1;74(17):4565-70. doi: 10.1158/0008-5472.CAN-14-1298. Epub 2014 Aug 18. Cancer Res. 2014. PMID: 25136070 Free PMC article. Review.
Cited by
-
Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.Biomedicines. 2021 Jun 26;9(7):736. doi: 10.3390/biomedicines9070736. Biomedicines. 2021. PMID: 34206903 Free PMC article. Review.
-
Genomic Context and Mechanisms of the ACVR1 Mutation in Fibrodysplasia Ossificans Progressiva.Biomedicines. 2021 Feb 5;9(2):154. doi: 10.3390/biomedicines9020154. Biomedicines. 2021. PMID: 33562470 Free PMC article. Review.
-
Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond.Inflamm Res. 2022 Aug;71(7-8):729-739. doi: 10.1007/s00011-022-01582-2. Epub 2022 May 6. Inflamm Res. 2022. PMID: 35523969 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources